酪酸梭菌活菌片联合马来酸曲美布汀、谷维素对IBS患者的疗效
|
摘要
目的探讨酪酸梭菌活菌片联合马来酸曲美布汀、谷维素对肠易激综合征患者的临床疗效。方法选择80例肠易激综合征患者,随机分为治疗组(n=40)和对照组(n=40)。治疗组患者采用酪酸梭菌活菌片联合马来酸曲美布汀、谷维素进行治疗,对照组患者采用马来酸曲美布汀和谷维素进行治疗。结果治疗组患者有效率高于对照组,两组疗效比较差异有统计学意义(P<0.05)。结论酪酸梭菌活菌片联合马来酸曲美布汀、谷维素对肠易激综合征患者疗效显著。
Objective To observe the clinical effect of Clostridium butyricum tablet combined with Trimebutine maleate and Oryzanol treating on patients with irritable bowel syndrome(IBS). Methods 80 cases of IBS were randomly divided into treatment group(n=40) or control group(n=40). The treatment group was given live Clostridium butyricum tablets, Trimebutine maleate and Oryzanol. The control group was given Trimebutine maleate and Oryzanol. Results The total efficiency rate in the treatment group was higher than in control group; the difference was statistically significant(P<0.05). Conclusion Clostridium butyricum tablet combined with Trimebutine maleate and Oryzanol has significant treatment effect on IBS.
Objective To observe the clinical effect of Clostridium butyricum tablet combined with Trimebutine maleate and Oryzanol treating on patients with irritable bowel syndrome(IBS). Methods 80 cases of IBS were randomly divided into treatment group(n=40) or control group(n=40). The treatment group was given live Clostridium butyricum tablets, Trimebutine maleate and Oryzanol. The control group was given Trimebutine maleate and Oryzanol. Results The total efficiency rate in the treatment group was higher than in control group; the difference was statistically significant(P<0.05). Conclusion Clostridium butyricum tablet combined with Trimebutine maleate and Oryzanol has significant treatment effect on IBS.
引文
[1] 左秀丽. 肠易激综合征病因及发病机制[J]. 中华消化杂志, 2015, 35(7): 434-438.
[2] ZENG Lifang, YAO Shuqiong. Effect of oryzanol combined with trimebutine maleate in treating irritable bowel syndrome[J]. Chin J Clin Ration Drug Use, 2015, 8(18): 16-17. (in Chinese) 曾利芳, 姚淑琼. 谷维素联合马来酸曲美布汀治疗肠易激综合征的临床疗效[J]. 临床合理用药杂志, 2015, 8(18): 16-17.
[3] LUO Hesheng, REN Haixia, ZHANG Facan, et al. The related factors and mechanisms of visceral hypersensitivity in patients with IBS[J]. Chin J Gastroenterol & Hepatol, 2016, 25(10): 1202-1206. (in Chinese) 罗和生, 任海霞, 张法灿, 等. IBS患者内脏高敏感性相关因素及其机制研究进展[J]. 胃肠病学和肝病学杂志, 2016, 25(10): 1202-1206.
[4] Bai T, Xia J, Jiang Y, et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey[J]. J Gastroenterol Hepatol, 2017, 32(5): 1018-1025.
[5] LIU Xiuli, LI Ling, REN Xifang, et al. Study on the efficacy of Trimebutine Maleate Combined with Pinaverium bromide in treatment of irritable bowel syndrome[J]. J Clin Digest Dis, 2011, 23(4): 210-211. (in Chinese) 刘修莉, 李玲, 任习芳, 等. 马来酸曲美布丁联合匹维溴胺治疗肠易激综合征的疗效观察[J]. 临床消化病杂志, 2011, 23(4): 210-211.
[6] ZHU Fenfang, HUANG Delian, OU Kaiyi. Clinical study of Jiawei Yigong powder in the treatment of intestinal dysfunctional abdominal pain[J]. Jilin Med J, 2018, 39(3): 462-463. (in Chinese) 朱芬芳, 黄德莲, 欧恺怡. 异功散加减治疗肠功能紊乱性腹痛的临床研究[J]. 吉林医学, 2018, 39(3): 462-463.
[7] Tan W, Zhang H, Luo HS, et al. Effects of trimebutine maleate on colonic motility through Ca?2+-activated K+ channels and L-type Ca?2+ channels[J]. Arch Pharm Res, 2011, 34(6): 979-985.
[8] Chen J. Research of the clinical effect of trimebutine and oryzanol as a treatment on patients with irritable bowel syndrome[J]. Jilin Med J, 2013, 34(32): 6699-6700. (in Chinese) 陈静. 曲美布汀、谷维素联合嗜酸乳杆菌治疗肠易激综合征的研究[J]. 吉林医学, 2013, 34(32): 6699-6700.
[9] LIN Zhang, ZU Xianpeng, XIE Haisheng, et al. Research progress in mechanism of intestinal microorganisms in human diseases[J]. Acta Pharma Sin, 2016, 51(6): 843-852. (in Chinese) 林璋, 祖先鹏, 谢海胜, 等. 肠道菌群与人体疾病发病机制的研究进展[J]. 药学学报, 2016, 51(6): 843-852.
[10] 曹亚男, 丰立娟, 王玉明. 益生菌辅助治疗肠易激综合征的机制研究进展[J]. 中华消化杂志, 2018, 38(4): 283-285.
[11] LU Jia. Mechanism of Lactobacillus in the treatment of irritable bowel syndrome[J]. Chin J Gastroenterol Hepatol, 2017, 26(2): 218-221. (in Chinese) 陆佳. 乳杆菌属治疗肠易激综合征的机制[J]. 胃肠病学和肝病学杂志, 2017, 26(2): 218-221.
[12] BI Zijuan, ZHANG Shisheng, YUAN Jianye. Probiotics and irritable bowel syndrome[J]. Med Rev, 2017, 23(1): 125-128. (in Chinese) 毕紫娟, 张仕晟, 袁建业. 益生菌与肠易激综合征[J]. 医学综述, 2017, 23(1): 125-128.
[13] Yao P, Tan F, Gao H, et al. Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2,4,6-trinitro-benzene sulfonic acid[J]. Molecul Med Rep, 2017, 15(4): 1973-1980.
[2] ZENG Lifang, YAO Shuqiong. Effect of oryzanol combined with trimebutine maleate in treating irritable bowel syndrome[J]. Chin J Clin Ration Drug Use, 2015, 8(18): 16-17. (in Chinese) 曾利芳, 姚淑琼. 谷维素联合马来酸曲美布汀治疗肠易激综合征的临床疗效[J]. 临床合理用药杂志, 2015, 8(18): 16-17.
[3] LUO Hesheng, REN Haixia, ZHANG Facan, et al. The related factors and mechanisms of visceral hypersensitivity in patients with IBS[J]. Chin J Gastroenterol & Hepatol, 2016, 25(10): 1202-1206. (in Chinese) 罗和生, 任海霞, 张法灿, 等. IBS患者内脏高敏感性相关因素及其机制研究进展[J]. 胃肠病学和肝病学杂志, 2016, 25(10): 1202-1206.
[4] Bai T, Xia J, Jiang Y, et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey[J]. J Gastroenterol Hepatol, 2017, 32(5): 1018-1025.
[5] LIU Xiuli, LI Ling, REN Xifang, et al. Study on the efficacy of Trimebutine Maleate Combined with Pinaverium bromide in treatment of irritable bowel syndrome[J]. J Clin Digest Dis, 2011, 23(4): 210-211. (in Chinese) 刘修莉, 李玲, 任习芳, 等. 马来酸曲美布丁联合匹维溴胺治疗肠易激综合征的疗效观察[J]. 临床消化病杂志, 2011, 23(4): 210-211.
[6] ZHU Fenfang, HUANG Delian, OU Kaiyi. Clinical study of Jiawei Yigong powder in the treatment of intestinal dysfunctional abdominal pain[J]. Jilin Med J, 2018, 39(3): 462-463. (in Chinese) 朱芬芳, 黄德莲, 欧恺怡. 异功散加减治疗肠功能紊乱性腹痛的临床研究[J]. 吉林医学, 2018, 39(3): 462-463.
[7] Tan W, Zhang H, Luo HS, et al. Effects of trimebutine maleate on colonic motility through Ca?2+-activated K+ channels and L-type Ca?2+ channels[J]. Arch Pharm Res, 2011, 34(6): 979-985.
[8] Chen J. Research of the clinical effect of trimebutine and oryzanol as a treatment on patients with irritable bowel syndrome[J]. Jilin Med J, 2013, 34(32): 6699-6700. (in Chinese) 陈静. 曲美布汀、谷维素联合嗜酸乳杆菌治疗肠易激综合征的研究[J]. 吉林医学, 2013, 34(32): 6699-6700.
[9] LIN Zhang, ZU Xianpeng, XIE Haisheng, et al. Research progress in mechanism of intestinal microorganisms in human diseases[J]. Acta Pharma Sin, 2016, 51(6): 843-852. (in Chinese) 林璋, 祖先鹏, 谢海胜, 等. 肠道菌群与人体疾病发病机制的研究进展[J]. 药学学报, 2016, 51(6): 843-852.
[10] 曹亚男, 丰立娟, 王玉明. 益生菌辅助治疗肠易激综合征的机制研究进展[J]. 中华消化杂志, 2018, 38(4): 283-285.
[11] LU Jia. Mechanism of Lactobacillus in the treatment of irritable bowel syndrome[J]. Chin J Gastroenterol Hepatol, 2017, 26(2): 218-221. (in Chinese) 陆佳. 乳杆菌属治疗肠易激综合征的机制[J]. 胃肠病学和肝病学杂志, 2017, 26(2): 218-221.
[12] BI Zijuan, ZHANG Shisheng, YUAN Jianye. Probiotics and irritable bowel syndrome[J]. Med Rev, 2017, 23(1): 125-128. (in Chinese) 毕紫娟, 张仕晟, 袁建业. 益生菌与肠易激综合征[J]. 医学综述, 2017, 23(1): 125-128.
[13] Yao P, Tan F, Gao H, et al. Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2,4,6-trinitro-benzene sulfonic acid[J]. Molecul Med Rep, 2017, 15(4): 1973-1980.